Provention Bio, Inc.
PRVB · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.43 | 0.83 | -0.11 | 1.21 |
| FCF Yield | -9.65% | -27.17% | -8.72% | -5.94% |
| EV / EBITDA | -6.17 | -2.40 | -7.90 | -12.80 |
| Quality | ||||
| ROIC | -78.27% | -101.55% | -88.70% | -52.65% |
| Gross Margin | 96.03% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.66 | 0.83 | 0.77 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 20.91% | -24.40% | -114.74% | -59.28% |
| Safety | ||||
| Net Debt / EBITDA | 0.16 | 0.67 | 1.02 | 0.88 |
| Interest Coverage | -123.59 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.42 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,903.82 | 0.00 | 0.00 | 0.00 |